Patients & CaregiversHealthcare Professionals - Opens new windowWorldwide - Opens new window
Quick links
HomeAbout MerckProductsNewsroomInvestor RelationsCareersResearchLicensingThe Merck Manuals
 

VIOXX® (rofecoxib) Information Center

The information set forth in the documents posted on this page was factually accurate on the date it was issued. While this information remains on Merck's Web site, the company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of this information should not rely on it as current or accurate after the issuance dates.


LITIGATION INFORMATION

14 May 2008 Merck Wins Appeal in VIOXX® Case
01 May 2008 Merck Extends Enrollment Deadline in Program to Resolve U.S. VIOXX® Product Liability Lawsuits
03 Mar 2008 Merck Progress Report on Enrollment in Program to Resolve U.S. VIOXX® Product Liability Lawsuits

Scientific Information

25 July 2007 Statement Regarding the Publications of Two VIOXX® Studies: The ViP Trial in Current Medical Research and Opinion and The VICTOR Trial in the New England Journal of Medicine (Adobe Acrobat File PDF* 22KB)
03 July 2007 VIOXX® Update: Statement on VICTOR Study (Adobe Acrobat File PDF* 22KB)
12 Sep 2006 Merck Statement about COX-2 Inhibitor Review Studies in the Journal of the American Medical Association (Adobe Acrobat File PDF* 23KB)

COMPANY STATEMENTS

06 Sep 2006 Report of The Honorable John S. Martin, Jr. to the Special Committee of the Board of Directors of Merck & Co., Inc. Concerning the Conduct of Senior Management in the Development and Marketing of VIOXX®
06 Sep 2006 Statement on the Martin Report by William G. Bowen (Adobe Acrobat File PDF* 8KB)
06 Sep 2006 Merck & Co., Inc. Statement on the Martin Report (Adobe Acrobat File PDF* 16KB)

Printer Friendly Page
 

Merck Response to JAMA Articles

VIOXX® CURRENT & POTENTIAL TRIAL SCHEDULE

 
Contact Merck Site Map Privacy Policy Terms of Use Copyright 1995-2008 Merck & Co., Inc.